Ginkgo Bioworks Holdings (DNA) Cash & Equivalents (2019 - 2026)

Ginkgo Bioworks Holdings has reported Cash & Equivalents for 8 years, with the latest figure at $143.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 53.95% year-over-year to $143.9 million; the trailing twelve-month figure through Mar 2026 stood at $143.9 million (down 53.95% YoY), and the FY2025 full-year result was $167.2 million, down 70.23% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $143.9 million, down from $167.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.5 billion in Q1 2022, with the low at $111.1 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $793.0 million across 5 years, with a median of $840.4 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 483.8% — and 2025, when it sank 81.98%.
• Ginkgo Bioworks Holdings' Cash & Equivalents stood at $1.3 billion in 2022, then dropped by 28.25% to $944.1 million in 2023, then tumbled by 40.52% to $561.6 million in 2024, then plunged by 70.23% to $167.2 million in 2025, then decreased by 13.96% to $143.9 million in 2026.
• The last three Cash & Equivalents figures came in at $143.9 million (Q1 2026), $167.2 million (Q4 2025), and $111.1 million (Q3 2025), per Business Quant data.